カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のペグ化リポソームドコルビシン市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Pegylated Liposomal Docorubicin Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19522）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19522
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：91
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のペグ化リポソームドコルビシン市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ペグ化リポソームドコルビシン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のペグ化リポソームドコルビシンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ペグ化リポソームドコルビシン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・10ml、5ml、25ml

用途別セグメントは次のように区分されます。
・乳がん、肝臓がん、腎臓がん、多発性骨髄腫、卵巣がん、その他

世界のペグ化リポソームドコルビシン市場の主要な市場プレーヤーは以下のとおりです。
・J&J、Sun Pharmaceutical、CSPC、Kinyond、Teva、Fudan-Zhangjiang、Zydus Cadila、TTY Biopharma

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ペグ化リポソームドコルビシン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なペグ化リポソームドコルビシンメーカーの企業概要、2019年～2022年までのペグ化リポソームドコルビシンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なペグ化リポソームドコルビシンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ペグ化リポソームドコルビシンの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのペグ化リポソームドコルビシンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのペグ化リポソームドコルビシン市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびペグ化リポソームドコルビシンの産業チェーンを掲載しています。
・第13、14、15章では、ペグ化リポソームドコルビシンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- ペグ化リポソームドコルビシンの概要
- 種類別分析（2017年vs2021年vs2028年）：10ml、5ml、25ml
- 用途別分析（2017年vs2021年vs2028年）：乳がん、肝臓がん、腎臓がん、多発性骨髄腫、卵巣がん、その他
- 世界のペグ化リポソームドコルビシン市場規模・予測
- 世界のペグ化リポソームドコルビシン生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- J&J、Sun Pharmaceutical、CSPC、Kinyond、Teva、Fudan-Zhangjiang、Zydus Cadila、TTY Biopharma
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：10ml、5ml、25ml
・用途別分析2017年-2028年：乳がん、肝臓がん、腎臓がん、多発性骨髄腫、卵巣がん、その他
・ペグ化リポソームドコルビシンの北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ペグ化リポソームドコルビシンのヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ペグ化リポソームドコルビシンのアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ペグ化リポソームドコルビシンの南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・ペグ化リポソームドコルビシンの中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Pegylated Liposomal Docorubicin market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Pegylated Liposomal Docorubicin market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Breast Cancer accounting for % of the Pegylated Liposomal Docorubicin global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 10ml segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Pegylated Liposomal Docorubicin include J&J, Sun Pharmaceutical, CSPC, Kinyond, and Teva, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Pegylated Liposomal Docorubicin market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
10ml
5ml
25ml
Market segment by Application can be divided into
Breast Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other
The key market players for global Pegylated Liposomal Docorubicin market are listed below:
J&J
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pegylated Liposomal Docorubicin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Pegylated Liposomal Docorubicin, with price, sales, revenue and global market share of Pegylated Liposomal Docorubicin from 2019 to 2022.
Chapter 3, the Pegylated Liposomal Docorubicin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pegylated Liposomal Docorubicin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Pegylated Liposomal Docorubicin market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pegylated Liposomal Docorubicin.
Chapter 13, 14, and 15, to describe Pegylated Liposomal Docorubicin sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Pegylated Liposomal Docorubicin Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Pegylated Liposomal Docorubicin Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 10ml
1.2.3 5ml
1.2.4 25ml
1.3 Market Analysis by Application
1.3.1 Overview: Global Pegylated Liposomal Docorubicin Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Breast Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Cancer
1.3.5 Multiple Myeloma
1.3.6 Ovarian Cancer
1.3.7 Other
1.4 Global Pegylated Liposomal Docorubicin Market Size & Forecast
1.4.1 Global Pegylated Liposomal Docorubicin Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Pegylated Liposomal Docorubicin Sales in Volume (2017-2028)
1.4.3 Global Pegylated Liposomal Docorubicin Price (2017-2028)
1.5 Global Pegylated Liposomal Docorubicin Production Capacity Analysis
1.5.1 Global Pegylated Liposomal Docorubicin Total Production Capacity (2017-2028)
1.5.2 Global Pegylated Liposomal Docorubicin Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Pegylated Liposomal Docorubicin Market Drivers
1.6.2 Pegylated Liposomal Docorubicin Market Restraints
1.6.3 Pegylated Liposomal Docorubicin Trends Analysis
2 Manufacturers Profiles
2.1 J&J
2.1.1 J&J Details
2.1.2 J&J Major Business
2.1.3 J&J Pegylated Liposomal Docorubicin Product and Services
2.1.4 J&J Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Sun Pharmaceutical
2.2.1 Sun Pharmaceutical Details
2.2.2 Sun Pharmaceutical Major Business
2.2.3 Sun Pharmaceutical Pegylated Liposomal Docorubicin Product and Services
2.2.4 Sun Pharmaceutical Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 CSPC
2.3.1 CSPC Details
2.3.2 CSPC Major Business
2.3.3 CSPC Pegylated Liposomal Docorubicin Product and Services
2.3.4 CSPC Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Kinyond
2.4.1 Kinyond Details
2.4.2 Kinyond Major Business
2.4.3 Kinyond Pegylated Liposomal Docorubicin Product and Services
2.4.4 Kinyond Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Teva
2.5.1 Teva Details
2.5.2 Teva Major Business
2.5.3 Teva Pegylated Liposomal Docorubicin Product and Services
2.5.4 Teva Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Fudan-Zhangjiang
2.6.1 Fudan-Zhangjiang Details
2.6.2 Fudan-Zhangjiang Major Business
2.6.3 Fudan-Zhangjiang Pegylated Liposomal Docorubicin Product and Services
2.6.4 Fudan-Zhangjiang Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Zydus Cadila
2.7.1 Zydus Cadila Details
2.7.2 Zydus Cadila Major Business
2.7.3 Zydus Cadila Pegylated Liposomal Docorubicin Product and Services
2.7.4 Zydus Cadila Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 TTY Biopharma
2.8.1 TTY Biopharma Details
2.8.2 TTY Biopharma Major Business
2.8.3 TTY Biopharma Pegylated Liposomal Docorubicin Product and Services
2.8.4 TTY Biopharma Pegylated Liposomal Docorubicin Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Pegylated Liposomal Docorubicin Breakdown Data by Manufacturer
3.1 Global Pegylated Liposomal Docorubicin Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Pegylated Liposomal Docorubicin Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Pegylated Liposomal Docorubicin
3.4 Market Concentration Rate
3.4.1 Top 3 Pegylated Liposomal Docorubicin Manufacturer Market Share in 2021
3.4.2 Top 6 Pegylated Liposomal Docorubicin Manufacturer Market Share in 2021
3.5 Global Pegylated Liposomal Docorubicin Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Pegylated Liposomal Docorubicin Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Pegylated Liposomal Docorubicin Market Size by Region
4.1.1 Global Pegylated Liposomal Docorubicin Sales in Volume by Region (2017-2028)
4.1.2 Global Pegylated Liposomal Docorubicin Revenue by Region (2017-2028)
4.2 North America Pegylated Liposomal Docorubicin Revenue (2017-2028)
4.3 Europe Pegylated Liposomal Docorubicin Revenue (2017-2028)
4.4 Asia-Pacific Pegylated Liposomal Docorubicin Revenue (2017-2028)
4.5 South America Pegylated Liposomal Docorubicin Revenue (2017-2028)
4.6 Middle East and Africa Pegylated Liposomal Docorubicin Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Pegylated Liposomal Docorubicin Sales in Volume by Type (2017-2028)
5.2 Global Pegylated Liposomal Docorubicin Revenue by Type (2017-2028)
5.3 Global Pegylated Liposomal Docorubicin Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Pegylated Liposomal Docorubicin Sales in Volume by Application (2017-2028)
6.2 Global Pegylated Liposomal Docorubicin Revenue by Application (2017-2028)
6.3 Global Pegylated Liposomal Docorubicin Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Pegylated Liposomal Docorubicin Sales by Type (2017-2028)
7.2 North America Pegylated Liposomal Docorubicin Sales by Application (2017-2028)
7.3 North America Pegylated Liposomal Docorubicin Market Size by Country
7.3.1 North America Pegylated Liposomal Docorubicin Sales in Volume by Country (2017-2028)
7.3.2 North America Pegylated Liposomal Docorubicin Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Pegylated Liposomal Docorubicin Sales by Type (2017-2028)
8.2 Europe Pegylated Liposomal Docorubicin Sales by Application (2017-2028)
8.3 Europe Pegylated Liposomal Docorubicin Market Size by Country
8.3.1 Europe Pegylated Liposomal Docorubicin Sales in Volume by Country (2017-2028)
8.3.2 Europe Pegylated Liposomal Docorubicin Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Pegylated Liposomal Docorubicin Sales by Type (2017-2028)
9.2 Asia-Pacific Pegylated Liposomal Docorubicin Sales by Application (2017-2028)
9.3 Asia-Pacific Pegylated Liposomal Docorubicin Market Size by Region
9.3.1 Asia-Pacific Pegylated Liposomal Docorubicin Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Pegylated Liposomal Docorubicin Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Pegylated Liposomal Docorubicin Sales by Type (2017-2028)
10.2 South America Pegylated Liposomal Docorubicin Sales by Application (2017-2028)
10.3 South America Pegylated Liposomal Docorubicin Market Size by Country
10.3.1 South America Pegylated Liposomal Docorubicin Sales in Volume by Country (2017-2028)
10.3.2 South America Pegylated Liposomal Docorubicin Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Pegylated Liposomal Docorubicin Sales by Type (2017-2028)
11.2 Middle East & Africa Pegylated Liposomal Docorubicin Sales by Application (2017-2028)
11.3 Middle East & Africa Pegylated Liposomal Docorubicin Market Size by Country
11.3.1 Middle East & Africa Pegylated Liposomal Docorubicin Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Pegylated Liposomal Docorubicin Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Pegylated Liposomal Docorubicin and Key Manufacturers
12.2 Manufacturing Costs Percentage of Pegylated Liposomal Docorubicin
12.3 Pegylated Liposomal Docorubicin Production Process
12.4 Pegylated Liposomal Docorubicin Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Pegylated Liposomal Docorubicin Typical Distributors
13.3 Pegylated Liposomal Docorubicin Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Pegylated Liposomal Docorubicin Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Pegylated Liposomal Docorubicin Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. J&J Basic Information, Manufacturing Base and Competitors
Table 4. J&J Major Business
Table 5. J&J Pegylated Liposomal Docorubicin Product and Services
Table 6. J&J Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 8. Sun Pharmaceutical Major Business
Table 9. Sun Pharmaceutical Pegylated Liposomal Docorubicin Product and Services
Table 10. Sun Pharmaceutical Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. CSPC Basic Information, Manufacturing Base and Competitors
Table 12. CSPC Major Business
Table 13. CSPC Pegylated Liposomal Docorubicin Product and Services
Table 14. CSPC Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Kinyond Basic Information, Manufacturing Base and Competitors
Table 16. Kinyond Major Business
Table 17. Kinyond Pegylated Liposomal Docorubicin Product and Services
Table 18. Kinyond Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Teva Basic Information, Manufacturing Base and Competitors
Table 20. Teva Major Business
Table 21. Teva Pegylated Liposomal Docorubicin Product and Services
Table 22. Teva Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Fudan-Zhangjiang Basic Information, Manufacturing Base and Competitors
Table 24. Fudan-Zhangjiang Major Business
Table 25. Fudan-Zhangjiang Pegylated Liposomal Docorubicin Product and Services
Table 26. Fudan-Zhangjiang Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Zydus Cadila Basic Information, Manufacturing Base and Competitors
Table 28. Zydus Cadila Major Business
Table 29. Zydus Cadila Pegylated Liposomal Docorubicin Product and Services
Table 30. Zydus Cadila Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. TTY Biopharma Basic Information, Manufacturing Base and Competitors
Table 32. TTY Biopharma Major Business
Table 33. TTY Biopharma Pegylated Liposomal Docorubicin Product and Services
Table 34. TTY Biopharma Pegylated Liposomal Docorubicin Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Global Pegylated Liposomal Docorubicin Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 36. Global Pegylated Liposomal Docorubicin Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 37. Market Position of Manufacturers in Pegylated Liposomal Docorubicin, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 38. Global Pegylated Liposomal Docorubicin Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Pegylated Liposomal Docorubicin Production Site of Key Manufacturer
Table 40. Pegylated Liposomal Docorubicin New Entrant and Capacity Expansion Plans
Table 41. Pegylated Liposomal Docorubicin Mergers & Acquisitions in the Past Five Years
Table 42. Global Pegylated Liposomal Docorubicin Sales by Region (2017-2022) & (K Units)
Table 43. Global Pegylated Liposomal Docorubicin Sales by Region (2023-2028) & (K Units)
Table 44. Global Pegylated Liposomal Docorubicin Revenue by Region (2017-2022) & (USD Million)
Table 45. Global Pegylated Liposomal Docorubicin Revenue by Region (2023-2028) & (USD Million)
Table 46. Global Pegylated Liposomal Docorubicin Sales by Type (2017-2022) & (K Units)
Table 47. Global Pegylated Liposomal Docorubicin Sales by Type (2023-2028) & (K Units)
Table 48. Global Pegylated Liposomal Docorubicin Revenue by Type (2017-2022) & (USD Million)
Table 49. Global Pegylated Liposomal Docorubicin Revenue by Type (2023-2028) & (USD Million)
Table 50. Global Pegylated Liposomal Docorubicin Price by Type (2017-2022) & (US$/Unit)
Table 51. Global Pegylated Liposomal Docorubicin Price by Type (2023-2028) & (US$/Unit)
Table 52. Global Pegylated Liposomal Docorubicin Sales by Application (2017-2022) & (K Units)
Table 53. Global Pegylated Liposomal Docorubicin Sales by Application (2023-2028) & (K Units)
Table 54. Global Pegylated Liposomal Docorubicin Revenue by Application (2017-2022) & (USD Million)
Table 55. Global Pegylated Liposomal Docorubicin Revenue by Application (2023-2028) & (USD Million)
Table 56. Global Pegylated Liposomal Docorubicin Price by Application (2017-2022) & (US$/Unit)
Table 57. Global Pegylated Liposomal Docorubicin Price by Application (2023-2028) & (US$/Unit)
Table 58. North America Pegylated Liposomal Docorubicin Sales by Country (2017-2022) & (K Units)
Table 59. North America Pegylated Liposomal Docorubicin Sales by Country (2023-2028) & (K Units)
Table 60. North America Pegylated Liposomal Docorubicin Revenue by Country (2017-2022) & (USD Million)
Table 61. North America Pegylated Liposomal Docorubicin Revenue by Country (2023-2028) & (USD Million)
Table 62. North America Pegylated Liposomal Docorubicin Sales by Type (2017-2022) & (K Units)
Table 63. North America Pegylated Liposomal Docorubicin Sales by Type (2023-2028) & (K Units)
Table 64. North America Pegylated Liposomal Docorubicin Sales by Application (2017-2022) & (K Units)
Table 65. North America Pegylated Liposomal Docorubicin Sales by Application (2023-2028) & (K Units)
Table 66. Europe Pegylated Liposomal Docorubicin Sales by Country (2017-2022) & (K Units)
Table 67. Europe Pegylated Liposomal Docorubicin Sales by Country (2023-2028) & (K Units)
Table 68. Europe Pegylated Liposomal Docorubicin Revenue by Country (2017-2022) & (USD Million)
Table 69. Europe Pegylated Liposomal Docorubicin Revenue by Country (2023-2028) & (USD Million)
Table 70. Europe Pegylated Liposomal Docorubicin Sales by Type (2017-2022) & (K Units)
Table 71. Europe Pegylated Liposomal Docorubicin Sales by Type (2023-2028) & (K Units)
Table 72. Europe Pegylated Liposomal Docorubicin Sales by Application (2017-2022) & (K Units)
Table 73. Europe Pegylated Liposomal Docorubicin Sales by Application (2023-2028) & (K Units)
Table 74. Asia-Pacific Pegylated Liposomal Docorubicin Sales by Region (2017-2022) & (K Units)
Table 75. Asia-Pacific Pegylated Liposomal Docorubicin Sales by Region (2023-2028) & (K Units)
Table 76. Asia-Pacific Pegylated Liposomal Docorubicin Revenue by Region (2017-2022) & (USD Million)
Table 77. Asia-Pacific Pegylated Liposomal Docorubicin Revenue by Region (2023-2028) & (USD Million)
Table 78. Asia-Pacific Pegylated Liposomal Docorubicin Sales by Type (2017-2022) & (K Units)
Table 79. Asia-Pacific Pegylated Liposomal Docorubicin Sales by Type (2023-2028) & (K Units)
Table 80. Asia-Pacific Pegylated Liposomal Docorubicin Sales by Application (2017-2022) & (K Units)
Table 81. Asia-Pacific Pegylated Liposomal Docorubicin Sales by Application (2023-2028) & (K Units)
Table 82. South America Pegylated Liposomal Docorubicin Sales by Country (2017-2022) & (K Units)
Table 83. South America Pegylated Liposomal Docorubicin Sales by Country (2023-2028) & (K Units)
Table 84. South America Pegylated Liposomal Docorubicin Revenue by Country (2017-2022) & (USD Million)
Table 85. South America Pegylated Liposomal Docorubicin Revenue by Country (2023-2028) & (USD Million)
Table 86. South America Pegylated Liposomal Docorubicin Sales by Type (2017-2022) & (K Units)
Table 87. South America Pegylated Liposomal Docorubicin Sales by Type (2023-2028) & (K Units)
Table 88. South America Pegylated Liposomal Docorubicin Sales by Application (2017-2022) & (K Units)
Table 89. South America Pegylated Liposomal Docorubicin Sales by Application (2023-2028) & (K Units)
Table 90. Middle East & Africa Pegylated Liposomal Docorubicin Sales by Region (2017-2022) & (K Units)
Table 91. Middle East & Africa Pegylated Liposomal Docorubicin Sales by Region (2023-2028) & (K Units)
Table 92. Middle East & Africa Pegylated Liposomal Docorubicin Revenue by Region (2017-2022) & (USD Million)
Table 93. Middle East & Africa Pegylated Liposomal Docorubicin Revenue by Region (2023-2028) & (USD Million)
Table 94. Middle East & Africa Pegylated Liposomal Docorubicin Sales by Type (2017-2022) & (K Units)
Table 95. Middle East & Africa Pegylated Liposomal Docorubicin Sales by Type (2023-2028) & (K Units)
Table 96. Middle East & Africa Pegylated Liposomal Docorubicin Sales by Application (2017-2022) & (K Units)
Table 97. Middle East & Africa Pegylated Liposomal Docorubicin Sales by Application (2023-2028) & (K Units)
Table 98. Pegylated Liposomal Docorubicin Raw Material
Table 99. Key Manufacturers of Pegylated Liposomal Docorubicin Raw Materials
Table 100. Direct Channel Pros & Cons
Table 101. Indirect Channel Pros & Cons
Table 102. Pegylated Liposomal Docorubicin Typical Distributors
Table 103. Pegylated Liposomal Docorubicin Typical Customers
List of Figures
Figure 1. Pegylated Liposomal Docorubicin Picture
Figure 2. Global Pegylated Liposomal Docorubicin Revenue Market Share by Type in 2021
Figure 3. 10ml
Figure 4. 5ml
Figure 5. 25ml
Figure 6. Global Pegylated Liposomal Docorubicin Revenue Market Share by Application in 2021
Figure 7. Breast Cancer
Figure 8. Liver Cancer
Figure 9. Kidney Cancer
Figure 10. Multiple Myeloma
Figure 11. Ovarian Cancer
Figure 12. Other
Figure 13. Global Pegylated Liposomal Docorubicin Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 14. Global Pegylated Liposomal Docorubicin Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Pegylated Liposomal Docorubicin Sales (2017-2028) & (K Units)
Figure 16. Global Pegylated Liposomal Docorubicin Price (2017-2028) & (US$/Unit)
Figure 17. Global Pegylated Liposomal Docorubicin Production Capacity (2017-2028) & (K Units)
Figure 18. Global Pegylated Liposomal Docorubicin Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. Pegylated Liposomal Docorubicin Market Drivers
Figure 20. Pegylated Liposomal Docorubicin Market Restraints
Figure 21. Pegylated Liposomal Docorubicin Market Trends
Figure 22. Global Pegylated Liposomal Docorubicin Sales Market Share by Manufacturer in 2021
Figure 23. Global Pegylated Liposomal Docorubicin Revenue Market Share by Manufacturer in 2021
Figure 24. Pegylated Liposomal Docorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 Pegylated Liposomal Docorubicin Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 Pegylated Liposomal Docorubicin Manufacturer (Revenue) Market Share in 2021
Figure 27. Global Pegylated Liposomal Docorubicin Sales Market Share by Region (2017-2028)
Figure 28. Global Pegylated Liposomal Docorubicin Revenue Market Share by Region (2017-2028)
Figure 29. North America Pegylated Liposomal Docorubicin Revenue (2017-2028) & (USD Million)
Figure 30. Europe Pegylated Liposomal Docorubicin Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific Pegylated Liposomal Docorubicin Revenue (2017-2028) & (USD Million)
Figure 32. South America Pegylated Liposomal Docorubicin Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa Pegylated Liposomal Docorubicin Revenue (2017-2028) & (USD Million)
Figure 34. Global Pegylated Liposomal Docorubicin Sales Market Share by Type (2017-2028)
Figure 35. Global Pegylated Liposomal Docorubicin Revenue Market Share by Type (2017-2028)
Figure 36. Global Pegylated Liposomal Docorubicin Price by Type (2017-2028) & (US$/Unit)
Figure 37. Global Pegylated Liposomal Docorubicin Sales Market Share by Application (2017-2028)
Figure 38. Global Pegylated Liposomal Docorubicin Revenue Market Share by Application (2017-2028)
Figure 39. Global Pegylated Liposomal Docorubicin Price by Application (2017-2028) & (US$/Unit)
Figure 40. North America Pegylated Liposomal Docorubicin Sales Market Share by Type (2017-2028)
Figure 41. North America Pegylated Liposomal Docorubicin Sales Market Share by Application (2017-2028)
Figure 42. North America Pegylated Liposomal Docorubicin Sales Market Share by Country (2017-2028)
Figure 43. North America Pegylated Liposomal Docorubicin Revenue Market Share by Country (2017-2028)
Figure 44. United States Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Pegylated Liposomal Docorubicin Sales Market Share by Type (2017-2028)
Figure 48. Europe Pegylated Liposomal Docorubicin Sales Market Share by Application (2017-2028)
Figure 49. Europe Pegylated Liposomal Docorubicin Sales Market Share by Country (2017-2028)
Figure 50. Europe Pegylated Liposomal Docorubicin Revenue Market Share by Country (2017-2028)
Figure 51. Germany Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Pegylated Liposomal Docorubicin Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Pegylated Liposomal Docorubicin Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Pegylated Liposomal Docorubicin Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific Pegylated Liposomal Docorubicin Revenue Market Share by Region (2017-2028)
Figure 60. China Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Pegylated Liposomal Docorubicin Sales Market Share by Type (2017-2028)
Figure 67. South America Pegylated Liposomal Docorubicin Sales Market Share by Application (2017-2028)
Figure 68. South America Pegylated Liposomal Docorubicin Sales Market Share by Country (2017-2028)
Figure 69. South America Pegylated Liposomal Docorubicin Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa Pegylated Liposomal Docorubicin Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa Pegylated Liposomal Docorubicin Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa Pegylated Liposomal Docorubicin Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa Pegylated Liposomal Docorubicin Revenue Market Share by Region (2017-2028)
Figure 76. Turkey Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa Pegylated Liposomal Docorubicin Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of Pegylated Liposomal Docorubicin in 2021
Figure 81. Manufacturing Process Analysis of Pegylated Liposomal Docorubicin
Figure 82. Pegylated Liposomal Docorubicin Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のリポソームアミカシン市場2022年：市場規模予測（～2028年）
  • 世界のリポソームミファムルチド市場2022年：市場規模予測（～2028年）
  • 世界のリポソームイリノテカン市場2022年：市場規模予測（～2028年）
  • 世界のリポソームブピバカイン市場2022年：市場規模予測（～2028年）
  • 世界のペグ化脂質市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19522 )"世界のペグ化リポソームドコルビシン市場2022年：市場規模予測（～2028年）" (英文：Global Pegylated Liposomal Docorubicin Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。